Stock To Watch: Rocket Pharma On Track

Rocket Pharmaceuticals, Inc. (RCKT), on Sunday, reported positive preliminary results from its phase I study of commercial-grade gene therapy RP-L102 "Process B" for Fanconi Anemia (FA) at the 61st annual meeting of American Society of Hematology (ASH).

Fanconi anemia is a rare genetic disorder, that mainly affects the bone marrow resulting in the decreased production of all types of blood cells.

The data were that of two pediatric patients of age 5 and 6 years who were treated with "Process B" RP-L102 prior to the development of severe bone marrow failure.
Treatment with 'Process B' RP-L102 at four to six months post-infusion showed early signs of engraftment and bone marrow restoration, noted the Company. Previously declining blood cell counts have been stabilized or even increased within six months of therapy.

"Process B" trial incorporates higher cell doses, transduction enhancers, and commercial-grade vector manufacturing and cell processing. No safety or tolerability issues have been reported.

The company expects to present additional long-term follow-up data from these patients in the first half of 2020.

A global registrational phase II study of "Process B" RP-L102 for Fanconi Anemia is currently underway, with primary endpoint of bone marrow MMC-resistance. The trial is expected to enroll five patients in the U.S. and five patients in Europe.

RCKT closed Friday's trading at $22.36, up 2.66%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission or FTC, has sued Walmart for allowing its money transfer services to be used by fraudsters, who fleeced consumers out of hundreds of millions of dollars. The retail giant is alleged to have looked the other way to pocket millions in fees while scammers took advantage of its failure to properly secure the money transfer services offered at Walmart stores. Home improvement retailer Bed Bath & Beyond, Inc. (BBBY) reported on Wednesday a net loss for first quarter that sharply widened from last year, hurt by hefty transient costs related to inventory markdown reserves and port-related supply chain fees. Both adjusted loss per share and net sales missed analysts' expectations. Tesla Inc. laid off about 200 employees in its Autopilot unit as the luxury electric car maker closed down its office in San Mateo, California as part of cost cutting efforts, reports said. The San Mateo office, where employees worked on improving the driver assistance systems, marketed as Autopilot, had about 350 employees before the cut.
Follow RTT